Department of Anesthesiology and Intensive Care, Södersjukhuset, Stockholm, Sweden.
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Acta Anaesthesiol Scand. 2021 Oct;65(9):1285-1292. doi: 10.1111/aas.13939. Epub 2021 Jun 25.
COVID-19 can cause severe disease with need of treatment in the intensive care unit (ICU) for several weeks. Increased knowledge is needed about the long-term consequences.
This is a single-center prospective follow-up study of COVID-19 patients admitted to the ICU for respiratory organ support between March and July 2020. Patients with invasive ventilation were compared with those with high-flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) regarding functional outcome and health-related qualify of life. The mean follow-up time was 5 months after ICU discharge and included clinical history, three well-validated questionnaires about health-related quality of life and psychological health, pulmonary function test, 6-minute walk test (6MWT) and work ability. Data were analyzed with multivariable general linear and logistic regression models with 95% confidence intervals.
Among 248 ICU patients, 200 patients survived. Of these, 113 patients came for follow-up. Seventy patients (62%) had received invasive ventilation. Most patients reported impaired health-related quality of life. Approximately one-third suffered from post-traumatic stress, anxiety and depression. Twenty-six percent had reduced total lung capacity, 34% had reduced 6MWT and 50% worked fulltime. The outcomes were similar regardless of ventilatory support, but invasive ventilation was associated with more bodily pain (MSD -19, 95% CI: -32 to -5) and <80% total lung capacity (OR 4.1, 95% CI: 1.3-16.5).
Among survivors of COVID-19 who required respiratory organ support, outcomes 5 months after discharge from ICU were largely similar among those requiring invasive compared to non-invasive ventilation.
COVID-19 可导致严重疾病,需要在重症监护病房(ICU)接受数周治疗。需要更多关于长期后果的知识。
这是一项对 2020 年 3 月至 7 月期间因呼吸器官支持而入住 ICU 的 COVID-19 患者进行的单中心前瞻性随访研究。比较了接受有创通气的患者与接受高流量鼻氧(HFNO)或无创通气(NIV)的患者的功能结局和与健康相关的生活质量。平均随访时间为 ICU 出院后 5 个月,包括临床病史、三个经过良好验证的与健康相关的生活质量和心理健康问卷、肺功能测试、6 分钟步行测试(6MWT)和工作能力。使用多元一般线性和逻辑回归模型进行数据分析,置信区间为 95%。
在 248 名 ICU 患者中,有 200 名患者存活。其中 113 名患者前来随访。70 名患者(62%)接受了有创通气。大多数患者报告健康相关的生活质量受损。约三分之一的患者患有创伤后应激、焦虑和抑郁。26%的患者总肺容量减少,34%的患者 6MWT 减少,50%的患者全职工作。通气支持方式不同,但结果相似,但有创通气与更多的躯体疼痛(MSD -19,95%CI:-32 至-5)和<80%的总肺容量(OR 4.1,95%CI:1.3-16.5)相关。
在需要呼吸器官支持的 COVID-19 幸存者中,ICU 出院后 5 个月的结局在需要有创通气与非创通气的患者之间基本相似。